ICU Medical Analysts Boost Their Forecasts Following Upbeat Q2 Earnings
ICU Medical Inc (NASDAQ: ICUI ) on Thursday posted upbeat earnings for the second quarter. The company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share. The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million. ICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00. Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.” ICU Medical shares rose 4.8% to $174.28 in pre-market trading. These analysts made changes to their price targets on ICU Medical following earnings announcement. Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165...
ICU Medical Inc (NASDAQ: ICUI ) on Thursday posted upbeat earnings for the second quarter.
The company reported quarterly earnings of $2.37 per share which beat the analyst consensus estimate of $1.91 per share.
The company reported quarterly sales of $551.700 million which beat the analyst consensus estimate of $533.428 million.
ICU Medical raised its FY2026 adjusted EPS guidance from $7.75-$8.45 to $8.60-$9.00.
Vivek Jain, ICU Medical’s Chief Executive Officer, said, “Second quarter results were ahead of our expectations for Infusion Systems and generally in line with expectations for the remainder of the business.” ICU Medical shares rose 4.8% to $174.28 in pre-market trading.
These analysts made changes to their price targets on ICU Medical following earnings announcement.
Needham analyst Mike Matson maintained the stock with a Buy and raised the price target from $165 to $187.
BTIG analyst Sam Eiber maintained the stock with a Buy and raised the price target from $170 to $200.
Considering buying ICUI stock? Here’s what analysts think: Photo via Shutterstock